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Abstract
Pathogen-specific antibody plays an important role in protection against pneumococcal carriage and infections. However,
neonates and infants exhibit impaired innate and adaptive immune responses, which result in their high susceptibility to
pneumococci. To protect neonates and infants against pneumococcal infection it is important to elicit specific protective
immune responses at very young ages. In this study, we investigated the protective immunity against pneumococcal
carriage, pneumonia, and sepsis induced by maternal immunization with pneumococcal surface protein A (PspA). Mother
mice were intranasally immunized with recombinant PspA (rPspA) and cholera toxin B subunit (CTB) prior to being mated.
Anti-PspA specific IgG, predominantly IgG1, was present at a high level in the serum and milk of immunized mothers and in
the sera of their pups. The pneumococcal densities in washed nasal tissues and in lung homogenate were significantly
reduced in pups delivered from and/or breast-fed by PspA-immunized mothers. Survival after fatal systemic infections with
various types of pneumococci was significantly extended in the pups, which had received anti-PspA antibody via the
placenta or through their milk. The current findings strongly suggest that maternal immunization with PspA is an attractive
strategy against pneumococcal infections during early childhood. (191 words)
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Introduction
Streptococcus pneumoniae frequently colonize the nasopharynx
asymptomatically. Especially following viral infections, S. pneumo-
niae are responsible for a significant proportion of bacterial
infectious diseases such as meningitis, otitis media, bacteremia,
and pneumonia [1]. The high incidence of pneumococcal disease
starts in the neonatal period and peaks around the first birthday.
Efforts have focused on the protection of children against
pneumococcal infections by immunization with vaccines.
The current 23-valent pneumococcal polysaccharide vaccine
(PPV) is efficacious in adults [2]. However, this polysaccharide-
based vaccines evoke little or no immune response in infants
younger than 2 years of age because of the weak immunogenicity
of its T cell independent polysaccharides [3,4]. Protein-conjugated
polysaccharide vaccines have been considered as an alternative
means to induce protective immunity in infants and children [5,6].
Human trials of a 7-valent polysaccharide conjugate vaccine
(PCV7) showed the capability to elicit solid protection against
invasive pneumococcal infection in children [7–11]. However,
PCV7 is not protective against strains with capsular types/groups
not present in the vaccine [12,13]. Shortly after the vaccine was
licensed, reports of serotype replacement began to appear [14–16].
Efforts to circumvent the problem of serotype replacement have
included expanding the number of polysaccharides in the vaccine
but this will not necessarily avoid the problem of subsequent
serotype replacement [6,17,18].
Furthermore, children younger than 2-years old usually have
low levels of IgG serum antibody to pathogen-specific antigens; a
results of age-related immaturity of immune responses [19,20].
The recurrent bacterial infections are thought to be in part due to
the subnormal levels of serum IgG antibody against causative
pathogens due to age-related immaturity [20–23]. Virolainen et al
showed that children who were infected most frequently with
pneumococci had the lowest titer of antibody to PspA among
children with invasive pneumococcal infections [24]. Simell et al
have made a similar observation showing that higher salivary
antibody levels to PspA are associated with a lower rate of
pneumococcal otitis media [25]. The need for protein-based
pneumococcal vaccines and their ability to protect against
pneumococcal infections during infant period has been further
emphasized by studies demonstrating a recent rapid increase in
both the prevalence and levels of resistance of multiple
antimicrobial resistant pneumococci [16]. Maternal immunization
with PPV is reported to reduce acute lower respiratory infections
in infants [26,27].
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e27102Pneumococcal surface protein A (PspA) is a promising candidate
for inclusion in a cost-effective protein-based pneumococcal
vaccine. PspA is an exposed virulence factor present in virtually
all pneumococcal strains. It is a highly immunogenic antigen and
affects host-pathogen interactions by inhibiting complement
activation by the classical and alternative pathways [28–30]. PspA
can elicit an antibody response that enhances complement
deposition and protects against nasal carriage, pneumonia, and
bacteremia in animal models [31–33]. Moreover, a human trial
showed an increase in specific anti-PspA immunoglobulin G (IgG)
levels after immunization with rPspA. Sera from the humans
immunized with rPspA were able to passively protect mice against
otherwise fatal challenge with various pneumococcal strains
[34,35].
Our preliminary study evaluated the efficacy of maternal
immunization with rPspA for protecting against lethal systemic
pneumococcal infections [36]. In the current study, we further
evaluated the relative roles of placental and milk/colostrum
derived antibody in the protection against pneumococcal invasive
disease and carriage in mouse pups following maternal immuni-
zation with rPspA. Prospective mother mice were intranasally
immunized with rPspA. Antibody levels in the breast milk and
serum of the mothers were measured and the transmission of
antibody and protection to the pups was evaluated by challenging
the offspring of mothers and the offspring of mice that were
fostered on immunized and non-immunized mothers.
Results
Anti-PspA specific antibodies in sera and milk of mother
mice
The levels of anti-PspA specific antibodies in sera of mother
BALB/cByJ mice were evaluated on day 0, 7, and 14 after they
gave birth (Fig. 1A). Anti-PspA specific IgG in sera of pups was
present at the birth and maintained during nursing periods among
PspA-immunized mother mice. Anti-PspA specific IgA and IgM
were also identified among PspA-immunized mother mice
although the levels of anti-PspA specific IgA and IgM in sera
were relatively low rather than anti-PspA specific IgG. The levels
of anti-PspA specific antibodies in sera among pre-immunized
mother mice and sham-immunized mother mice were below the
detections limit (data not shown).
The levels of anti-PspA specific antibodies in breast milk from
mother mice were also evaluated on day 0, 7, and 14 after the
birth (Fig. 1B). In breast milk higher levels of IgG PspA-specific
antibody were detected relative to IgA or IgM specific antibody.
The levels of anti-PspA specific antibodies in breast milk among
pre-immunized mother mice and sham-immunized mother mice
were below the detections limit (data not shown).
IgG subclasses of antibody to PspA in sera and milk of
mother mice
On the day of birth (day 0) the predominant IgG subclass of IgG
antibody to PspA in sera from PspA-immunized mother mice was
IgG1, followed by IgG2a and IgG2b (Fig. 2A). The levels of anti-
PspA specific IgG2a gradually increased from day 0 to day 14
(p,0.05), while the levels of anti-PspA specific IgG1 and IgG2b
did not change significantly. The mean IgG1/IgG2a ratio in the
sera of individual mice gradually decreased from 3.1 on day 0 to
1.1 on day 14 (p,0.05). The levels of IgG3 were below the
detection limit.
In the breast milk, IgG1 was also the predominant anti-PspA
specific IgG subclass followed by IgG2a and IgG2b from PspA-
immunized mother mice (Fig. 2B). The levels of anti-PspA specific
IgG2a and IgG2b increased from day 0 to day 14 (p,0.05), while
IgG1 did not change. The mean IgG1/IgG2a ratio in breast milk
from individual mice gradually decreased from 5.7 on day 0 to 1.7
on day 14 (p,0.05). The levels of IgG3 were below the detection
limit.
Anti-PspA specific antibodies in sera of offspring
The changes of anti-PspA specific IgG in the sera of offspring
were evaluated on day 0, 7, and 14 after the birth (Fig. 3).
Offspring delivered from PspA-immunized mothers (Group A and
Group C) had high levels of anti-PspA specific IgG in sera at birth.
The levels of anti-PspA specific IgG in sera from offspring of
immune mothers that were breast-fed by PspA-immunized mother
mice (Group A) were maintained at the high levels on day 7 and
day 14. In contrast the levels of anti-PspA specific IgG in sera from
offspring of immune mothers who were breast-fed by sham-
immunized mother mice (Group C) rapidly declined after the
birth. On the other hand, offspring delivered from sham-
immunized mother mice (Group B and Group D) did not have
anti-PspA specific IgG in sera at the birth. The PspA-specific IgG
in sera from offspring of sham-immune mothers that were breast-
fed by PspA-immunized mothers (Group B) gradually increased
and reached levels similar to those of Group A on day 7 to day 14.
The control offspring (Group D) from sham-immunized mothers
who were nursed on sham-immune mothers did not have anti-
PspA specific IgG in their sera. Anti-PspA specific IgA and IgM
were not detected in sera of all offspring.
Anti-PspA specific IgG subclasses in sera of offspring
The levels of anti-PspA specific IgG subclass in sera of offspring
were also evaluated on day 0, 7, and 14 after the birth (Fig. 4). The
predominant IgG subclass in sera of offspring in all groups was
IgG1 followed by IgG2a and IgG2b at the birth. In all offspring,
the levels of IgG3 were below the detection limit.
In Group A, the levels of IgG1 and IgG2a were not changed
during the period from day 0 to day 14. In contrast to the results of
group A mothers’ sera, the mean IgG1/IgG2a ratio calculated
from the individual pup sera also did not change during the period
from day 0 to day 14. This indicates that IgG2 antibody was less
efficiently transported to the progeny by nursing than the IgG1
antibody. In Group B, offspring did not have anti-PspA specific
IgG in sera at the birth. The levels of anti-PspA specific IgG1 in
sera gradually increased and reached the similar levels to those of
the offspring in Group A on day 7 to day 14 (p,0.05 and p,0.01,
respectively). The mean IgG1/IgG2a ratio for group B was higher
on day 7 than that of Group A (p,0.05). On day 14 the mean
IgG1/IgG2a ratio for Group B was higher than that of Group A,
but the difference was not statistically significant. In Group C,
anti-PspA specific serum IgG1 was predominant on day 0 and the
levels did not change during the period from day 0 to day 14. The
IgG2b levels in the Group C mice gradually decreased from day 0
to day 14. The mean IgG1/IgG2a ratios for Group C mice were
higher than those of Group A mice on day 0 and increased from
day 7 to day 14 (p,0.01).
Protection against nasal carriage of pneumococci by
maternal immunization with PspA among offspring
The carriage density of pneumococci in nasal washes and
homogenized washed nasal tissue were evaluated at day 2 after
intranasal challenge with 5610
5 CFUs of TIGR4 pneumococci.
The numbers of CFUs in nasal washes were not different among
groups. The median Log10 CFUs of pneumococci in nasal washes
of Group A, B, C, and D was 4.55, 4.45, 4.24, and 4.49,
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homogenized washed nasal tissue was significantly different among
groups (Fig. 5). The median Log10 CFUs of pneumococci in nasal
tissue of Group A, B, C, and D was 4.56, 4.77, 4.91, and 5.01,
respectively. The carriage density of washed nasal tissues of Group
A was statistically lower than those of Group D (control) (p,0.05).
The Log10 CFUs of washed nasal tissue of Group B tended to be
lower than that of Group D (p,0.1). There was no difference in
CFUs in nasal tissue of Groups C and D. Thus, maternal
immunization with PspA appeared to result in only a modest
reduction of nasal colonization of nasal tissue among offspring
nursed on immunized dams.
Protection against lung infection by maternal
immunization with PspA among offspring
Inoculation of 7-day old offspring with a relatively large volume
of inoculum intranasally under anesthesia caused enough
pneumococci to be aspirated to cause infection of the lung. The
5610
5 CFUs of TIGR4 pneumococci in 10 ml sterile Ringer’s
solution were inoculated intranasally into anesthetized offspring.
At 3 days after inoculation, all mice were alive and were
euthanized so that the numbers of CFU in their lungs and blood
could be determined (Fig. 6). The median Log10 CFUs of
pneumococci in Group A, B, C, and D was 1.91, 1.58, 1.90,
and 2.73, respectively. The mean number of Log10 CFUs in lung
homogenate in Group A and Group B were each significantly
reduced in comparison to Group D (p,0.05 and p,0.01,
respectively). Mice from immunized mothers who were not nursed
by immune mothers (Group C) had fewer median CFU than the
non-immune Group D mice, this difference was not statistically
significant. In all cases there were no CFU or only a few in the
blood. As a result, we can be confident that the protection seen
was the result of events in the lung and not protection against
sepsis. Based on these results immunity achieved through nursing
appeared to be especially important for protection in this model.
Protection against fatal systemic pneumococcal
infections among offspring through maternal
immunization with rPspA
Survival of offspring after intraperitoneal infection with 1610
4
CFUs of TIGR4 strain was evaluated. The survival after the
otherwise fatal systemic pneumococcal infection was significantly
extended in Groups A, B, and C as compared to the sham-
immunized Group D controls (p,0.01 for each group) (Fig. 7).
With this model, transfers of antibody by the placenta and/or
nursing were all exhibited significant protection.
In all of the above studies we immunized with TIGR4 derived
PspA and challenged with TIGR4 capsular type 4 strain.
However, there is some variability in PspA and it is found in
two broad serologically cross-reactive families; PspA serologic/
sequence family 1 (PspA1) and PspA serologic/sequence family 2
(PspA2) [37]. It is generally recommended that in the development
of a human vaccine that one PspA1 protein and one to two PspA2
proteins be used [38]. However, there have also been findings that
in some studies that strong cross-protection could be observed
between PspA1 and PspA2 families [39–43].
TIGR4 strain is PspA2 and we evaluated its ability to elicit
immunity to four different PspA1 strains. In each case the highest
Figure 1. Anti-PspA specific antibodies in sera and milk of mother mice. Female mice were intranasally immunized twice each week with
1 mg of rPspA and 4 mg CTB for first 2 weeks and with 1 mg rPspA alone for the last week. The levels of anti-PspA specific IgG, IgA and IgM antibodies
in sera (A) and breast milk (B) were determined by PspA-specific ELISA on day 0, 7 and 14 after the birth. The values shown are the mean 6 S.E.
concentrations (ng/ml) taken from PspA-immunized mother (n=16) and sham-immunized mother (n=14). The levels of anti-PspA specific antibodies
in sera and breast milk from sham-immunized mice were below the limit of detection.
doi:10.1371/journal.pone.0027102.g001
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with 1 mg of rPspA and 4 mg CTB for first 2 weeks and with 1 mg rPspA alone for the last week. The levels of anti-PspA specific IgG1, IgG2a, IgG2b and
IgG3 antibodies in sera (A) and breast milk (B) were determined by PspA-specific ELISA on day 0, 7 and 14 after the birth. The values shown are the
mean 6 S.E. concentrations (ng/ml) taken from PspA-immunized mother (n=16) and sham-immunized mother (n=14). The mean values of IgG1/
IgG2a antibody to PspA in the sera of the individual mother’s sera were 3.1, 2.1 and 1.1 for day 0, 7, and 14, respectively. The mean IgG1/IgG2a anti-
PspA values for the individual mother’s milk samples were 5.7, 6.5, and 1.7 for day 0, 7, and 14, respectively. The levels of anti-PspA specific IgG
subclasses in sera and breast milk from sham-immunized mice were below the detections limit. * p,0.05 when compared with mice at day 0 by
ANOVA test or Kruskal-Wallis test with Dunn’s multiple comparison test. n.d. not determined.
doi:10.1371/journal.pone.0027102.g002
Figure 3. Anti-PspA specific antibodies in sera of offspring. The levels of anti-PspA specific IgG in sera of offspring were determined by PspA-
specific ELISA at days 0, 7, and 14 after the birth. Group A mice were the offspring delivered from PspA-immunized mothers and breast-fed by the
same mothers (n=26). Group B mice were offspring from sham-immunized mothers and breast-fed by PspA-immunized mothers (n=22). Group C
mice were offspring from PspA-immunized mothers and breast-fed by sham-immunized mothers (n=27). Group D mice were offspring from sham-
immunized mother and breast-fed by the same mother (n=18). The values shown are the mean 6 S.E. concentrations (ng/ml). * p,0.05 and **
p,0.01 when compared with offspring in Group D by ANOVA test with Dunn’s multiple comparison test.
doi:10.1371/journal.pone.0027102.g003
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control mice. Survival of offspring infected intraperitoneally with
PspA1 strain D39 (capsular serotype 2, 50 CFUs/mouse) was
significantly extended (p,0.01) compare to that of controls.
Survival of offspring infected with two other PspA1 strains of
EF3030 (capsular serotype 19F, 5610
6 CFUs/mouse) and
BG7322 (capsular serotype 6B, 20 CFUs/mouse) were weakly
extended compared to that of controls (Fig. 8). However, there
were no significant differences in survival times among offspring
infected the PspA1 strain with L82016 (capsular serotype 6B,
5610
6 CFUs/mouse). These finding makes it clear that even when
immunization is not with the homologous PspA family it is still
sometimes possible to see a protective response in the pups.
However, these data are consistent with the expectation that a
PspA vaccine should include PspAs of both major PspA families.
Discussion
During the first few months of life, when the human immune
system is still immature, infants depend largely on passively
acquired maternal IgG antibodies to protect themselves against
invasive pathogens [20]. As in young humans, neonatal and infant
mice are more susceptible to pneumococcal colonization and
subsequent infection than are adults. Neonatal mouse macro-
phages show impaired innate and adaptive immune responses to
pneumococci, which might explain the increased susceptibility to
pneumococcal colonization in vivo [44]. The vaccines used to
induce protective antibody early in childhood serve to minimize
this window of natural susceptibility, but all such vaccines leave a
window of susceptibility during the time that the initial immune
response is induced. Immunization of women before pregnancy is
a strategy that has been proven to reduce infection risks in mothers
and infants for more than one pathogen [45–50].
Many recent pre-clinical studies in animals have focused on
developing effective mucosal vaccines to combat the susceptibility
of children to respiratory bacteria [51–53]. Our previous
immunization studies using the outer membrane protein P6 of
Haemophilus influenzae showed that maternal intranasal immuniza-
tion could induce anti-P6 specific IgG antibody responses in
mother’s sera and breast milk at birth and that the immune
response was maintained for 14 days during the nursing period
[54]. Similar to those previous results, our present studies showed
that anti-PspA specific antibody predominant in IgG was observed
in PspA-immunized mother mice and was transported to their
offspring via placenta and breast milk.
Mouse colostrums or breast milk have been reported to contain
higher amounts of IgG antibody compared to IgA and IgM
antibodies [55]. In mice, IgG antibody in mother’s sera is
transferred from mother to fetus through placenta by neonatal Fc
receptor, FcRn. This antibody is initially collected in the yolk sacs
of prenatal mice and rats [56,57]. Moreover, IgG antibody in
breast milk is also transferred from intestine lumen to systemic
circulation in neonate mice [56,57]. This transport of IgG
antibody is mediated by FcRn expressed in the intestine of mice
Figure 4. Anti-PspA specific IgG subclasses in sera of offspring. The levels of anti-PspA specific IgG subclasses in offspring’s sera were
determined by PspA-specific ELISA on day 0, 7, and 14 after birth. Group A (n=26), B (n=22), C (n=27), and D (n=18) mice were the same mice as
described in figure 3. The values shown are the mean 6 S.E. concentrations (ng/ml). The mean values of IgG1/IgG2a ratio were also shown. * p,0.05
and **p,0.01 are for comparisons with offspring in Group D for PspA-specific IgG subclasses or with offspring on day 0 for the IgG1/IgG2a ratio by
ANOVA test with Dunn’s multiple comparison test.
doi:10.1371/journal.pone.0027102.g004
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by receptor-mediated transcytosis in humans and other animals
represents a novel concept in mucosal immunology. Recent studies
have also demonstrated receptor-mediated IgG transport demon-
strated across the lung of mice [62]. The FcRn expressing
bronchia epithelial cells transports IgG across the mucosal surface
of lung from lumen to serosa. The neonatal FcRn mediates the
transport of IgG across polarized epithelial cells lining mucosal
surface [63,64]. Furthermore, not only is IgG transmitted to
progeny, but functional maternal immunoglobulin secreting cell or
B cells can also be transferred to the neonate in both mouse and
human [65,66].
In the present study of antibody to PspA, we further evaluated
the protection of offspring against nasal carriage, lung infection,
and fatal sepsis caused by pneumococci. Nasopharyngeal coloni-
zation is the initial step in the pathogenesis of infection caused by
S. pneumoniae. Since carriage is considered to precede the
development of subsequent fatal pneumococcal invasive diseases,
the protection against carriage can also protect against subsequent
disease [67].
The numbers of pneumococci colonizing closely associated with
the nasal tissue were reduced by maternal immunization with
PspA. On the other hand, the numbers of pneumococci washed
from nasal surfaces were not different among groups (data not
shown). Our earlier study demonstrated that during nasal
colonization of mice with pneumococci, the majority of the
colonizing pneumococci are tissue-associated and of the opaque
phenotype [68]. This observation suggests that the opaque
pneumococci may have either invaded the nasal tissue or may
be sequestered in deep crypts and are not removed by the nasal
wash. While secretory-IgA (SIgA) antibodies play an important
role in the protection against nasopharyngeal colonization of
Figure 5. Protection against nasal carriage of pneumococci by
maternal immunization with PspA among offspring. Offspring at
7-day-old were intranasally challenged with 1610
5 CFU TIGR4 strain
(5 ml/mouse) without anesthesia. Two days after challenge, nasal
washes and homogenized washed nasal tissues were collected and
the numbers of pneumococci colonies were determined. No evidence
of protection was observed in CFUs in nasal washes (not shown).
Results are shown for CFU in homogenized washed nasal tissue. Each
dot represents the Log10 CFU/mouse. Each horizontal line depicts the
median Log10 CFU/mouse. Group A (n=11), B (n=10), C (n=13), and D
(n=15) mice were produced in the same manner as the corresponding
groups in figure 3. Group A differed from Group D at p,0.05 by Kruskal-
Wallis test with Dunn’s multiple comparison test.
doi:10.1371/journal.pone.0027102.g005
Figure 6. Protection against lung infection by maternal
immunization with PspA among offspring. Seven-day-old mice
were intranasally challenged with 5610
5 CFU TIGR4 strain (10 ml/
mouse) with anesthesia. Three days after challenge, lungs were
collected and the numbers of pneumococci colonies in the lung
homogenate were determined. Each dot shows the Log10 CFU/mouse.
Each horizontal line shows the median Log10 CFU/mouse. Group A
(n=18), B (n=16), C (n=20), and D (n=27) mice were produced in the
same manner as the corresponding groups in figure 3. p,0.05 and
p,0.01 are p-values for differences between the indicated group and
the non-immune mice in Group D by Kruskal-Wallis test with Dunn’s
multiple comparison test.
doi:10.1371/journal.pone.0027102.g006
Figure 7. Protection against fatal systemic pneumococcal
infections by maternal immunization with PspA among
offspring. Offspring at 10-days of age were intraperitonally challenged
with 1610
4 CFU TIGR4 strain (100 ml/mouse) with anesthesia. After
challenge, offspring were monitored for 5 days to determine survival.
Group A (n=24), B (n=28), C (n=24), and D (n=38) mice were
produced in the same manner as the corresponding groups in figure 3.
Group A mice are offspring delivered from PspA-immunized mothers
and breast-fed by the same mothers (n=24). Group B mice are
offspring from sham-immunized mothers and breast-fed by PspA-
immunized mothers (n=28). Group C mice are offspring from PspA-
immunized mothers and breast-fed by sham-immunized mothers
(n=24). Group D mice are offspring from sham-immunized mothers
and breast-fed by the same mothers (n=38). * p,0.01 when compared
with control offspring in Group D by Kaplan-Meier test with Log rank
test.
doi:10.1371/journal.pone.0027102.g007
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pneumococci once they have invaded the nasal tissues [69].
Ferreira et al reported that the reduction of nasal colonization
was strongly associated with increased levels of IgG2a complement
fixing antibody and lower levels of IgG1 antibody which had less
complement fixing activity [70,71]. As a consequence, lower
IgG1/IgG2a ratios were also correlated with lower levels of
colonization [70,71]. In this study, IgG1/IgG2a ratio was
decreased on day 0 to 14 in both mother’s sera and breast milk.
As for the offspring’s sera in our study, the anti-PspA specific
IgG2a antibodies were increased in sera from offspring in Group A
where immunized mothers nursed their own pups. A balanced
IgG1/IgG2a antibody response was maintained in the Group A
offspring over time. The fact that the only group that showed even
a hint of protection against colonization was group A, which had
the highest relative concentrations of IgG2a as compared to IgG1,
is consistent with the earlier published observations from
experiments with adult mice [71]. Our failure to see stronger
protection against carriage, may in retrospect be due the fact that
our mice were sacrificed only 2 days post challenge. In most adult
mouse studies sacrifice at 5-day, 7-day, or later time points, which
may have permit the cumulative actions of immunity over time
may have had larger effects on colonization.
As compared to colonization, where the protective effects were
quite modest if at all, maternal immunization was clearly
protectected the offspring against pneumococcal lung infections
and fatal sepsis. The absence of bacteremia and sepsis in the
aspiration-pneumonia infection model might suggest that the
observed protection against lung infection results from direct
protection in the lung, rather than just being realized through a
protection against septicemia. Offspring delivered from mother
mice immunized intranasally with PspA were protected from
systemic pneumococcal infections. Intranasal immunization with
PspA has been shown to protect adult mice against pneumonia
and fatal sepsis and occasionally against nasal carriage [72,73].
The present studies have shown that similar immunizations of
mother mice can protect progeny in these models and that the
protection is to some extent independent of the PspA family of the
challenge strain.
While significant protection was seen against infection of
TIGR4 PspA2 strain by maternal immunization with homologous
PspA2, we observed strong portection against invasive infection
with only one of four PspA1 challenge strains. The current findings
caution that for protein vaccines one must take care to include
PspAs representative of both major PspA families: PspA1 and
PspA2. Darrieux M. et al. demonstrated that a chimeric fusion
Figure 8. Cross-protection against fatal infections with pneumococcal strains expressing family 1 PspA. As in the prior studies the
mother mice were immunized with a rPspA2 of strain TIGR4. Offspring at 10-days of age were intraperitoneally challenged with D39 (PspA1, serotype
2; 50 CFUs/mouse), BG7322 (PspA1, serotype 6B; 20 CFUs/mouse), EF3030 (PspA1, serotype 19F; 5610
6 CFUs/mouse), and L82016 (PspA1 serotype 6B,
5610
6 CFUs/mouse) in 100 ml with anesthesia. After challenge, the mice were monitored for 10 days to determine the day of death. Group A mice
were offspring delivered from PspA-immunized mothers and breast-fed by the same mothers (n=6 for D39, n=10 for BG7322, n=7 for EF3030, n=6
for L82016). Group B mice were offspring from sham-immunized mothers and breast-fed by a PspA-immunized mothers (n=7 for D39, n=11 for
BG7322, n=4 for EF3030, n=10 for L82016). Group C were offspring from PspA-immunized mothers and breast-fed by sham-immunized mothers
(n=9 for D39, n=11 for BG7322, n=5 for EF3030, n=11 for L82016). Group D mice were offspring from sham-immunized mothers and breast-fed by
the same mothers (n=9 for D39, n=5 for BG7322, n=6 for EF3030, n=6 for L82016). p,0.05 and p,0.01 for the indicated comparisons with
offspring in Group D by Kruskal-Wallis test with Dunn’s multiple comparison test are shown.
doi:10.1371/journal.pone.0027102.g008
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pneumococcal infection with strains bearing diverse PspA
fragments [74].
Although the immune systems are different between mice and
human being, maternal intranasal immunization can induce
specific immune responses in mothers and that this immunity is
effectively transferred to their infants. The findings strongly
suggest that maternal mucosal (intranasal) immunization would
be an attractive procedure to elicit early immunity against S.
pneumoniae infections among young children. It is anticipated that
this immunity is mediated by transplacental immunoglobulin (Ig)
transferred during pregnancy and via breast milk. Naturally
acquired IgA and IgG antibodies to PspA have been shown to be
transferred from mother to child and to protect against early
pneumococcal infections. Baril et al reported that transplacental
transfer of IgG antibody to PspA was more efficient with IgG1
than IgG2 [75]. This finding is not inconsistent with a potential
protective role of transplacental IgG in humans since human IgG1
and IgG2 are both highly complement fixing like IgG2 in the
mouse [76–78]. Mouse IgG1 is poorly complement fixing and this
observation may explain its weaker association with protection in
this paper and in earlier studies [70].
Thus, infants may be able to be protected by prior
immunization of their mothers. If pneumococcal protein-based
vaccines are found to be efficacious, the direct correlation of the
magnitude of the mother’s IgG to PspA and that of the infant
could be an indicator that the immunization of women of
childbearing age with protein pneumococcal vaccine could protect
their infants from pneumococcal disease. A clinical trial could be
designed to test the potential of immunization of young adult
women or infants with a combination of pneumococcal proteins as
an experimental vaccination approach to prevent against invasive
pneumococcal disease.
In conclusion, the current findings suggest that maternal
intranasal immunization would be an attractive procedure against
pneumococcal infections among during childhood because the
transport of the specific antibody to the neonate can be expected
to occur through both the placenta and mother’s milk.
Materials and Methods
Bacterial strains
S. pneumoniae strains TIGR4 (serotype 4, PspA2), D39 (serotype
2, PspA1), EF3030 (serotype 19F, PspA1), L82016 (serotype 6B,
PspA1), and BG7322 (serotype 6B, PspA1) used in this study. All of
S. pneumoniae strains were grown in Todd-Hewitt broth with 0.5%
yeast extract (THY) at 37uC until mild log-phase and stocked in
aliquots at known CFU concentrations in THY broth containing
10% glycerol at 280uC until use for infections.
Recombinant PspA
rPspA for immunization was PspA2/TIGR4 including a-helical
region [37]. Briefly, an internal gene fragment of pspA was
amplified by polymerase chain reaction from S. pneumoniae strain
TIGR4. The amplified gene fragment of the expected sizes were
sub-cloned by TOPO TA Cloning Kit (Invitrogen Inc., Carlsbad,
CA, USA) and then cloned to the pET20b vector (Novagen Inc.,
Madison, WI, USA) incorporating between NcoI and XhoI sites.
The pET20b vector containing pspA fragment was transformed
into the E. coli strain BL21 (DE3) for protein production.
Expression of rPspA was induced with 1 mM isopropylthio-ß-D-
galactoside (IPTG) for 2 h. The six-histidine-tagged rPspA was
purified by nickel affinity chromatography.
Immunization
Four-week-old BALB/cByJ female mice were maintained
under specific pathogen-free condition. They were immunized
twice each week with 1 mg of rPspA mixed with 4 mg cholera
toxin B subunit (CTB) (List Biological Labs, Campbell, CA, USA)
on the Mondays and Fridays of 3 consecutive weeks [32]. During
the first two weeks the immunization included CTB. During the
last week, the two immunizations contained antigen alone.
Control mice received only CTB for the first 2 weeks and only
saline for the last week. After the final immunization, the female
mice were mated with male mice for two weeks. Offspring were
obtained approximately 3 weeks after mating. All animal
experiments were approved by the Institutional Animal Ethics
Committee of the Wakayama Medical University (Project
Number: 237 and 429).
Division of offspring
In order to evaluate the importance of feeding status, we further
divided offspring into 4 groups as follows. In Group A, offspring
were delivered form PspA-immunized mother and breast-fed by
their PspA-immunized mother. In Group B, offspring were
delivered from sham-immunized mother and breast-fed by
PspA-immunized mother. In Group C, offspring were delivered
from PspA-immunized mother and breast-fed by sham-immunized
mother. In Group D, offspring were delivered from sham-
immunized mother and breast-fed by sham-immunized mother.
Enzyme linked immunosorbent assay (ELISA)
Sera and milk were collected from mother mice at birth of their
pups (day0), and on days 7, 14 days after their birth. Sera were also
collected from offspring at birth (day 0), 7, 14 days after birth.
Anti-PspA specific antibodies in milk and sera were evaluated by
the solid ELISA. Briefly, 96 well microplates (MaxiSorp, Nunc,
Roskilde, Denmark) were coated with 50 ml of rPspA (2 mg/ml) in
phosphate buffered saline (PBS) overnight at 4uC. After washing
three times with PBS containing 0.05% Tween 20 (PBS-T), the
wells were blocked for 1 h with casein buffer (0.2% casein, 0.05%
Tween 20 in PBS) at room temperature. Then, 50 ml of samples
diluted with casein buffer were incubated at 4uC overnight. To
determined PspA specific antibody isotypes, after washing with
PBS-T, the plate was incubated with 50 ml of 1/3000 biotinylated
antibody to mouse IgG, IgA or IgM (Southern Biotechnology
Associates, Birmingham, AL, USA) diluted in casein buffer for 2 h
at room temperature, respectively. Then, after washing with PBS-
T, the plate was incubated with 1/4000 alkaline phosphatase
conjugated streptavidin (Southern Biotechnology Associates) for
2 h at room temperature. Color was developed with p–nitrophenyl
phosphate (PNPP) (Sigma Chemical Co., St. Louis, MO, USA)
and the optical density of each well was measured by a
spectrophotometer at 405 nm. The subclass of anti-PspA specific
IgG antibody was also determined using 1/2000 biotinylated
antibodies to mouse IgG1, IgG2a, IgG2b or IgG3 (Southern
Biotechnology Associates).
Challenge with pneumococci in nasal carriage,
pneumonia, and bacteremia models
For nasal carriage, 7-day-old offspring were given the bacteria
in a 5-ml volume of sterile Ringer’s solution in a single nostril
without anesthesia. Two days after inoculation, offspring were
euthanized by CO2 inhalation and the nasal cavity of each
offspring was washed by flushing 100 ml of Ringer’s solution into
the trachea and out through the nostrils. Next, the nasal tissue
including nasal conchae, olfactory epithelium, and sinus mucosa
Maternal Immunization against S. pneumoniae
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solution as described previously [79].
For lung infection, the bacteria were given in a 10-ml volume of
sterile Ringer’s solution in a single nostril to 7-day-old offspring
anesthetized with diethylether (Wako Chemical Co., Japan) to
facilitate aspiration. After 3 days, offspring were sacrificed and the
lungs were removed. The lobes of the lungs were placed into 1 ml
of Ringer’s solution in a stomacher bag and homogenized. Blood
from the euthanized mice was also plated to determine numbers of
CFU/ml. All specimens were serially diluted and plated on blood
agar plates, blood agar plates supplemented with 4 mg/ml
gentamicin, and blood agar plates supplemented with 4 mg/ml
gentamicin and 5 mg/ml optochin. The viable pneumococcal
counts were determined after overnight incubation.
For systemic fatal infection, 10-day-old offspring were given the
bacteria in 0.1 ml sterile Ringer’s solution intraperitoneally with
anesthesia. The offspring were observed for 5 days to determine
survival or the day of death.
Statistics
The levels of PspA specific antibody in each group were
compared by ANOVA test with Dunn’s multiple comparison test.
The IgG1/IgG2a ratio was compared by Kruskal-Wallis test with
Dunn’s multiple comparison test. The carriage density of
challenged offspring in each group was expressed as log10 CFUs
and compared by Kruskal-Wallis test with Dunn’s multiple
comparison test. Survival of challenged offspring in each group
was assessed by Kaplan-Meier test with Log-rank test. Statistical
values were calculated with Prism 4 (GraphPad Software, La Jolla,
CA, USA). For all comparison, p,0.05 was considered to
represent a significant difference.
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